Pfizer’s oral diabetes drug demonstrated promising weight loss that some experts say could work just as fast as Novo Nordisk’s highly sought after Ozempic.
In the mid-stage trial, over 400 adults with Type 2 diabetes took Pfizer’s danuglipron twice a day or a placebo pill for roughly four months to test its efficacy.
The results showed that every dose of the danuglipron pill reduced patients’ blood sugar at week 16 compared to the placebo.